

Federico Innocenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2034982/publications.pdf>

Version: 2024-02-01

84
papers

5,847
citations

136950

32
h-index

76900

74
g-index

96
all docs

96
docs citations

96
times ranked

9165
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan. <i>Journal of Clinical Oncology</i> , 2004, 22, 1382-1388.	1.6	927
2	Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). <i>Journal of Clinical Oncology</i> , 2010, 28, 3617-3622.	1.6	758
3	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	7.4	670
4	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	21.4	294
5	Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics. <i>Journal of Clinical Oncology</i> , 2009, 27, 2604-2614.	1.6	236
6	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. <i>Journal of Clinical Oncology</i> , 2019, 37, 1217-1227.	1.6	234
7	Predictive Role of the <i>UGT1A1</i> , <i>UGT1A7</i> , and <i>UGT1A9</i> Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan. <i>Journal of Clinical Oncology</i> , 2009, 27, 2457-2465.	1.6	216
8	Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue. <i>PLoS Genetics</i> , 2011, 7, e1002078.	3.5	191
9	Variation in the glucose transporter gene <i>SLC2A2</i> is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	21.4	165
10	Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 866-871.	1.6	156
11	Haplotype structure of the <i>UDP-glucuronosyltransferase 1A1</i> promoter in different ethnic groups. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 725-733.	5.7	154
12	Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the <i>UGT1A1</i> Genotype of Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2328-2334.	1.6	121
13	Haplotypes of variants in the <i>UDP-glucuronosyltransferase 1A9</i> and <i>1A1</i> genes. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 295-301.	1.5	105
14	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	1.6	101
15	A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303. <i>Clinical Cancer Research</i> , 2012, 18, 577-584.	7.0	91
16	Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. <i>Pharmacogenomics</i> , 2006, 7, 1211-1221.	1.3	81
17	The Role of SN-38 Exposure, <i>UGT1A1</i> Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 78-86.	2.0	77
18	A Common Allele in <i>FGF21</i> Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. <i>Cell Reports</i> , 2018, 23, 327-336.	6.4	76

#	ARTICLE	IF	CITATIONS
19	Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 683-697.	1.5	73
20	Irinogenetics: What Is the Right Star?. <i>Journal of Clinical Oncology</i> , 2006, 24, 2221-2224.	1.6	54
21	A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 490-502.	4.7	53
22	Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet?. <i>Pharmacotherapy</i> , 2008, 28, 755-768.	2.6	52
23	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 3047-3053.	1.6	51
24	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	1.6	51
25	All You Need to Know About <i>DPYD</i> Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. <i>JCO Oncology Practice</i> , 2020, 16, 793-798.	2.9	46
26	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	7.0	44
27	Genomic Characterization of Metformin Hepatic Response. <i>PLoS Genetics</i> , 2016, 12, e1006449.	3.5	41
28	Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e84940.	2.5	40
29	Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2000, 39, 315-325.	3.5	39
30	The Genotype for <i>DPYD</i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 994-1002.	4.7	39
31	Irinogenetics and UGT1A: from genotypes to haplotypes*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 495-500.	4.7	37
32	Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 918-924.	7.0	35
33	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
34	Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. <i>Oncology</i> , 2003, 17, 52-5.	0.5	28
35	The Use of Genomic Information to Optimize Cancer Chemotherapy. <i>Seminars in Oncology</i> , 2011, 38, 186-195.	2.2	27
36	Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. <i>Cancer Research</i> , 2019, 79, 231-241.	0.9	24

#	ARTICLE	IF	CITATIONS
37	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	7.1	24
38	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
39	All You Need to Know About <i>UGT1A1</i> Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. <i>JCO Oncology Practice</i> , 2022, 18, 270-277.	2.9	24
40	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021, 44, 2673-2682.	8.6	23
41	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	2.9	22
42	Genetic effects on liver chromatin accessibility identify disease regulatory variants. <i>American Journal of Human Genetics</i> , 2021, 108, 1169-1189.	6.2	22
43	Implications of genome-wide association studies in cancer therapeutics. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 370-380.	2.4	21
44	A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1383-1393.	4.7	20
45	Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 2249-2260.	2.8	19
46	Individualizing Dosing of Irinotecan. <i>Clinical Cancer Research</i> , 2010, 16, 371-372.	7.0	16
47	Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1067-1075.	1.1	15
48	Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 374-381.	1.5	14
49	Pharmacogenomic-Guided Therapy in Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 616-625.	4.7	14
50	DPYD Variants to Predict 5-FU Toxicity: The Ultimate Proof. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju351-dju351.	6.3	13
51	The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. <i>PLoS ONE</i> , 2018, 13, e0202272.	2.5	13
52	Liver expression quantitative trait loci: a foundation for pharmacogenomic research. <i>Frontiers in Genetics</i> , 2012, 3, 153.	2.3	12
53	Genetic variation determines VEGF-A plasma levels in cancer patients. <i>Scientific Reports</i> , 2018, 8, 16332.	3.3	10
54	Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand?. <i>Pharmacogenomics</i> , 2013, 14, 1-4.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	2.9	8
56	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Network Open, 2020, 3, e2023500.	5.9	8
57	Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis, 2022, 25, 47-55.	7.2	8
58	Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. International Journal of Cancer, 2022, 150, 279-289.	5.1	8
59	Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. British Journal of Cancer, 2022, 126, 265-274.	6.4	8
60	Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. British Journal of Cancer, 2022, 126, 640-651.	6.4	7
61	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene, 2022, 41, 260-267.	5.9	7
62	PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors. Pharmacogenomics Journal, 2022, 22, 82-88.	2.0	7
63	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	2.9	6
64	Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). Cancer, 2021, 127, 3801-3808.	4.1	6
65	A Guide to the Current Web-Based Resources in Pharmacogenomics. Methods in Molecular Biology, 2013, 1015, 293-310.	0.9	6
66	The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemotherapy and Pharmacology, 2009, 63, 881-887.	2.3	4
67	Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine. American Journal of Pharmaceutical Education, 2018, 82, 6652.	2.1	4
68	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes and Control, 2019, 30, 757-765.	1.8	4
69	An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenetics and Genomics, 2019, 29, 123-131.	1.5	4
70	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. AAPS Journal, 2020, 22, 59.	4.4	4
71	Bringing a genomic perspective to the safety of drug treatment in oncology. F1000Research, 2017, 6, 385.	1.6	3
72	Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors. Clinical Pharmacology and Therapeutics, 2022, 112, 316-326.	4.7	3

#	ARTICLE	IF	CITATIONS
73	Research Highlights: Highlights from the latest articles in germline genomics in oncology. Pharmacogenomics, 2012, 13, 1113-1114.	1.3	2
74	fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies. BMC Bioinformatics, 2019, 20, 333.	2.6	2
75	KDR genetic predictor of toxicities induced by sorafenib and regorafenib. Pharmacogenomics Journal, 2022, 22, 251-257.	2.0	2
76	Pharmacogenomics of Chemotherapeutic Agents in Cancer Treatment. , 0, , 283-309.		1
77	Reply to A. D. King et al. JCO Oncology Practice, 2021, 17, 455-455.	2.9	1
78	Polygenic Risk Scores for Blood Pressure to Assess the Risk of Severe Bevacizumab-Induced Hypertension in Cancer Patients (Alliance). Clinical Pharmacology and Therapeutics, 2022, 112, 364-371.	4.7	1
79	Role ofUGT1A1*6in irinogenetics in Asians. Personalized Medicine, 2007, 4, 431-434.	1.5	0
80	Reply to L. Casadaban et al. Journal of Clinical Oncology, 2017, 35, 1373-1374.	1.6	0
81	The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?. Translational Oncology, 2021, 14, 100952.	3.7	0
82	One SNP for both cancer risk and survival in colorectal cancer: two for the price of one?. Pharmacogenomics, 2012, 13, 1114.	1.3	0
83	Challenges in the development and use of pharmacogenomic markers in oncology. The Journal of Supportive Oncology, 2007, 5, 15-6.	2.3	0
84	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682. Diabetes Care, 2022, 45, e82-e83.	8.6	0